Hadwiono Muhammad R, Hartopo Anggoro B, Wasityastuti Widya, Anggrahini Dyah W, Ryanto Gusty R T, Emoto Noriaki, Dinarti Lucia K
Department of Cardiology and Vascular Medicine, Faculty of Medicine Public Health and Nursing Universitas Gadjah Mada - Dr. Sardjito Hospital Yogyakarta Indonesia.
Master in Biomedical Sciences Program, Faculty of Medicine, Public Health and Nursing Universitas Gadjah Mada Yogyakarta Indonesia.
Pulm Circ. 2023 Aug 21;13(3):e12280. doi: 10.1002/pul2.12280. eCollection 2023 Jul.
Activin A, a member of TGF-β superfamily, has been implicated in the pathogenesis of pulmonary artery hypertension (PAH). PAH due to congenital heart disease (CHD-PAH) is a major problem in developing countries. Activin A may have a role in PAH development and progression among uncorrected CHD. In this comparative study, serum activin A level was significantly increased in subjects with uncorrected CHD without the presence of PH and were more significantly risen in CHD-PAH, as compared to control. The utilization of serum activin A measurement seems promising to identify uncorrected CHD patients with PAH development and progression.
激活素A是转化生长因子-β超家族的成员之一，与肺动脉高压（PAH）的发病机制有关。先天性心脏病所致的PAH（CHD-PAH）是发展中国家的一个主要问题。激活素A可能在未矫正的先天性心脏病患者发生PAH及病情进展中起作用。在这项对比研究中，与对照组相比，未矫正的先天性心脏病且无肺动脉高压（PH）的受试者血清激活素A水平显著升高，而CHD-PAH患者血清激活素A水平升高更显著。检测血清激活素A水平似乎有望识别有PAH发生及病情进展的未矫正先天性心脏病患者。
